USNANYSEMedicinal Chemicals & Botanical ProductsUS GAAP · USD

USANA Health Sciences, Inc

USANA Health Sciences is a U.S.-based developer and manufacturer of nutritional supplements, personal care products, and skincare products sold internationally through direct selling. The company also operates a direct-to-consumer business through Hiya, which offers children's health and wellness products.

Liikevaihto925milj. USD
+0,0 %v/v
Liikevoitto (EBIT)37,4milj. USD
+0,0 %v/v
EBIT-marginaali4,0%
+0,0 %-yks.v/v
Nettotulos10,8milj. USD
+0,0 %v/v
Vapaa kassavirta8,5milj. USD
+0,0 %v/v

Tilikausi 2026 · muutos edellisvuodesta

Kehitys 2021–2026

02505007501 0001 250milj. USD2021: 1 135 milj. USD2021: EBIT 176 milj. USD20212022: 999 milj. USD2022: EBIT 108 milj. USD20222023: 921 milj. USD2023: EBIT 93 milj. USD20232024: 855 milj. USD2024: EBIT 66 milj. USD20242025: 925 milj. USD2025: EBIT 37 milj. USD20252026: 925 milj. USD2026: EBIT 37 milj. USD202692537
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
USANA Nutritionals88 %

Core supplement lines including Optimizers, Essentials/CellSentials, and related nutritional products.

USANA Foods6 %

Food and active nutrition products sold within the direct selling channel.

Personal care and Skincare5 %

Topical personal care and skincare products distributed through the direct selling network.

Hiya direct-to-consumer1 %

Children's health and wellness products sold directly to consumers under the Hiya brand.

Asiakkaat

USANA sells primarily to independent Brand Partners/Associates and Preferred Customers in its direct selling business. Brand Partners buy products for resale and personal use, while Preferred Customers buy for personal consumption; Hiya sells directly to parents and families seeking children's wellness products.

Brand Partners / Associates

Independent distributors who purchase USANA products for resale and personal use; they are central to the direct selling model.

Preferred Customers

Consumers who buy USANA products for personal use and do not resell them.

Retail customers

End consumers reached through Associates in certain markets, buying for household use and wellness needs.

Parents and families

Hiya buyers purchasing children's vitamins and wellness products through the direct-to-consumer channel.

Strategia

USANA's strategy centers on growing active Customers in its direct selling network while supporting Brand Partners with a compensation-based distribution model. The company is also building a second growth channel through Hiya, expanding its direct-to-consumer presence in children's health and wellness products.

Increase active CustomersLyhyt aikaväli

The direct selling model depends on customer count and repeat purchasing to drive product volume.

Scale Hiya direct-to-consumerKeskipitkä aikaväli

Hiya adds channel diversification and reduces reliance on the traditional direct selling model.

Maintain financial flexibilityLyhyt aikaväli

Liquidity supports operations, acquisitions, stock repurchases, and market expansion.

Maantiede

Q2/2026

USANA operates in multiple international markets, with a large share of direct selling net sales generated outside the United States. The company also maintains cash and operating exposure in China and other markets, which makes foreign exchange movements an important part of reported results and liquidity management.

Asia Pacific49 %
Kina33 %
USA18 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

USANA is exposed to customer concentration and distributor-network risk because sales depend on recruiting and retaining active Customers and Brand Partners. The company also faces foreign exchange, China-related operating exposure, and acquisition/integration risk from its multi-channel structure and international footprint.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Active Customer decline1Foreign exchange volatility2China operating exposure3Distributor compensation and incentive pressure4Acquisition integration risk5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Active Customer declineVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Direct selling revenue is driven by the number of active Customers and their spend.

    Kohdistuu: Direct selling segment

  2. Foreign exchange volatilityVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Most sales are outside the U.S., so translation affects reported revenue and earnings.

    Kohdistuu: International operations

  3. China operating exposureVaikutus: KorkeaTodennäköisyys: Kohtalainen

    China is a major market and cash concentration area, increasing regulatory and transfer risk.

    Kohdistuu: China

  4. Distributor compensation and incentive pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Brand Partner incentives are a major cost and are tied to sales activity.

    Kohdistuu: Direct selling model

  5. Acquisition integration riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Hiya adds a new channel, brand, and operating model that must be integrated successfully.

    Kohdistuu: Hiya direct-to-consumer

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition by channel

Sales are split between direct selling and direct-to-consumer, which can have different timing and return patterns.

Vaikutus: Reported revenue and comparability

Brand Partner incentives

Incentives are a major operating cost in the direct selling model and can vary with sales activity.

Vaikutus: Operating margin and earnings

Foreign currency translation

Most sales occur outside the United States, so exchange rates affect reported results and cash balances.

Vaikutus: Revenue, earnings, and liquidity

Amortization of acquired intangibles

Hiya acquisition accounting creates amortization expense that affects reported profitability.

Vaikutus: Operating income and net income

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 24.9.2026

USANA Health Sciences, Inc (NYSE) – Medicinal Chemicals & Botanical Products | Analyysi – Clarifo